GLIOBLASTOMA, IDH-WILDTYPE

Clinical trials for GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.

Never miss a new study

Get alerted when new GLIOBLASTOMA, IDH-WILDTYPE trials appear

Sign up with your email to follow new studies for GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 2 Not yet finished but already full! 4 Completed 1 Terminated 1

Scientists hunt for safe dose in new brain cancer drug combo

Disease control Completed

This early-stage study tested adding a drug called regorafenib to the standard treatment for a fast-growing brain cancer called glioblastoma. The main goal was to find the highest dose of regorafenib that patients could safely take alongside their usual chemotherapy and radiation…

Matched conditions: GLIOBLASTOMA, IDH-WILDTYPE

Phase: PHASE1 • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

GLIOBLASTOMA, IDH-WILDTYPE

Get alerted when new GLIOBLASTOMA, IDH-WILDTYPE trials appear

Scientists hunt for safe dose in new brain cancer drug combo